Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients

Use of liposomal bupivacaine has not been reported specifically for use in adolescent bariatric surgery. Our rationale is based on the notion that for most minimally invasive procedures, methods currently used for pain control provide good outcomes that liposomal bupivacaine may not necessarily be able to improve upon. It is critically important to minimize the narcotics for our bariatric surgical patients so they are mobilized early and frequently to minimize their risk for a deep venous thrombosis, which could become a pulmonary embolus. In addition, as these patients are prone to constipation after their operation as a result of their 2 week protein sparing liquid diet preoperatively, avoiding narcotics can reduce their chances of further challenges in return of their bowel function. For these reasons, we seek to investigate whether incorporating liposomal bupivacaine in the analgesic regimen for patients undergoing a laparoscopic sleeve gastrectomy will lead to improvements in patient-reported outcomes and decreased opioid utilization.

Inclusion criteria

• patients who are undergoing a laparoscopic sleeve gastrectomy for severe obesity who are between 13 and 2018 years of age.
• Only patients treated at the Children's Hospital of Richmond at VCU will be included.

Exclusion criteria

• patients less than 13 or greater than 2018 years of age
• patients with an allergy to bupivacaine
• any patients undergoing any additional procedures at the time of the laparoscopic sleeve gastrectomy.
• English or Spanish proficiency will be necessary.